Lower pneumonitis incidence among patients treated with PD-L1 may be due to the action mechanism of an anti-PD-1 agent blocking the PD-L1 and PD-L2 interactions, while anti-PD-L1 agents allow interactions between PD-L2 and PD-1 [35]. Here, PDCD1LG2 is linked to pneumonitis.